The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A study into the pharmacodynamic biomarker effects of olaparib (PARP Inhibitor) ± degarelix (GnRH antagonist) given prior to radical prostatectomy (RP) CANCAP03.
 
Simon Pacey
Consulting or Advisory Role - Roche (Inst)
Research Funding - AstraZeneca (Inst)
 
Mark David Linch
Consulting or Advisory Role - BioNTech Diagnostics; Bristol-Myers Squibb; Janssen
Research Funding - Astellas Medivation; AstraZeneca; Bristol-Myers Squibb; Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck
 
Howard Kynaston
No Relationships to Disclose
 
Anne Warren
No Relationships to Disclose
 
Alex Freeman
No Relationships to Disclose
 
Ruth Tysoe
No Relationships to Disclose
 
Greg Shaw
Consulting or Advisory Role - Angle
 
Krishna Narahari
No Relationships to Disclose
 
Satish Kumar
No Relationships to Disclose
 
Henno Martin
No Relationships to Disclose
 
Bihani Kularatne
No Relationships to Disclose
 
Vincent Gnanapragasam
No Relationships to Disclose
 
Barry Davies
Employment - AstraZeneca
 
Josephine Khan
No Relationships to Disclose
 
Ola Bratt
Honoraria - AstraZeneca
 
Harveer Dev
No Relationships to Disclose
 
Charles Massie
No Relationships to Disclose
 
Nimish Shah
No Relationships to Disclose